CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses

類似資料

• iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
  著者:: Corgnac, Stéphanie, 等
  出版事項: (2014)
• Tumor targeting of innate and adaptive immunity by the adoptive cell transfer of engineered T lymphocytes co-expressing iNKT and tumor-specific MHC-I TCRs
  著者:: Tschumi, Benjamin O, 等
  出版事項: (2014)
• Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in mice
  著者:: Stirnemann, Kathrin, 等
  出版事項: (2008)
• Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
  著者:: Zhang, Lianjun, 等
  出版事項: (2017)
• Transcription factor Bcl11b sustains iNKT1 and iNKT2 cell programs, restricts iNKT17 cell program, and governs iNKT cell survival
  著者:: Uddin, Mohammad Nizam, 等
  出版事項: (2016)